Xin Lang Cai Jing·2026-02-25 05:12Group 1 - The core viewpoint of the news is that Junshi Biosciences has experienced fluctuations in its stock price and trading volume, with a recent increase of 2.10% in its share price, reaching 34.99 CNY per share, and a total market capitalization of 35.92 billion CNY [1] - As of February 25, the stock has seen a year-to-date increase of 2.43%, but has declined by 2.04% over the last five trading days, 0.85% over the last twenty days, and 2.13% over the last sixty days [2] - Junshi Biosciences, established on December 27, 2012, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] Group 2 - As of September 30, 2025, Junshi Biosciences reported a revenue of 1.806 billion CNY, reflecting a year-on-year growth of 42.06%, while the net profit attributable to shareholders was -596 million CNY, showing a year-on-year increase of 35.72% [2] - The company is categorized under the pharmaceutical and biotechnology industry, specifically in the biopharmaceutical sector, and is involved in various concept sectors including monkeypox, exclusive drugs, COVID-19 medications, and virus prevention [2] - Institutional holdings show that as of September 30, 2025, the top ten circulating shareholders include E Fund's SSE STAR 50 ETF and Huaxia's SSE STAR 50 Component ETF, both of which have reduced their holdings compared to the previous period [3]